Abstract
Background There is convincing evidence that overall adiposity (as measured by body mass index) increases the risks of several cancers. Whether there are similar relationships between these cancers and the distribution of adiposity is unclear.
Methods In the absence of well-powered individual studies we utilised two-sample Mendelian randomization (MR) to examine causal relationships of five adiposity distribution traits (abdominal subcutaneous adipose tissue; ASAT, visceral adipose tissue; VAT and gluteofemoral adipose tissue; GFAT, liver fat, and pancreas fat) with the risks of 12 obesity-related cancers (endometrial, ovarian, breast, colorectal, pancreas, multiple myeloma, liver, kidney (renal cell), thyroid, gallbladder, oesophageal adenocarcinoma, and meningioma) and cancer subtypes/subsites. We then used multivariable MR to investigate whether plausible molecular intermediates could potentially be mediating the relationships identified. We used the largest available GWAS from European populations for all traits (sample size across all GWAS ranged from 8,407 to 728,896 (median: 57,249); cancer GWAS ranged from 279 to 133,384 cases (median: 4,532) and 3,456 to 727,247 controls (median: 68,802)).
Results We found evidence that higher genetically predicted ASAT increased risks of endometrial cancer (inverse variance-weighted (IVW) odds ratio (IVW OR) per standard deviation (SD) higher genetically predicted ASAT = 1.79, 95% confidence interval (CI) = 1.18 to 2.71), liver cancer (IVW OR per SD higher genetically predicted ASAT = 3.83, 95% CI = 1.39 to 10.53) and oesophageal adenocarcinoma (IVW OR per SD higher genetically predicted ASAT = 2.34, 95% CI = 1.15 to 4.78). Conversely, we found evidence that higher genetically predicted GFAT decreased risks of breast cancer (IVW OR per SD higher genetically predicted GFAT= 0.77, 95% CI = 0.62 to 0.97) and meningioma (IVW OR per SD higher genetically predicted GFAT = 0.53, 95% CI = 0.32 to 0.90). We also found evidence for an effect of higher genetically predicted VAT and liver fat on increased liver cancer risk (IVW ORs per SD higher genetically predicted adiposity trait = 4.29 and 4.09, 95% CIs = 1.41 to 13.07 and 2.29 to 7.28, respectively). Multivariable MR analyses suggested that traits related to insulin signalling, sex hormones, and inflammation may play important roles in mediating the effects of adiposity distribution on obesity-related cancers.
Conclusions Our analyses provide novel insights into the variability of the effect of adiposity distribution on cancer risk, with respect to both adiposity trait and cancer type, which would not be possible in a conventional observational analysis given the lack of available samples with all required traits measured. These findings demonstrate that adipose tissue at different anatomical locations may have differential effects on adiposity-related molecular traits. These insights enhance our understanding of the complex relationship between adiposity and cancer risk and highlight the importance of adipose tissue distribution alongside maintaining a healthy weight overall for cancer prevention.
Competing Interest Statement
Tom G Richardson is employed full-time by GlaxoSmithKline outside of the research presented in this manuscript. Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization. This article is the result of the scientific work of Neil Murphy while he was affiliated at IARC. Robert C Grant received a graduate scholarship from Pfizer and provided consulting or advisory roles for AstraZeneca, Tempus, Eisai, Incyte, Knight Therapeutics, Guardant Health, and Ipsen. Dimitri J Pournaras has been funded by the Royal College of Surgeons of England. He receives consulting fees from Johnson & Johnson, Novo Nordisk, GSK, Sandoz, Pfizer and payments for lectures, presentations, and educational events from Johnson & Johnson, Medtronic, and Novo Nordisk.
Funding Statement
EH is supported by a Cancer Research UK Population Research Committee Studentship (C18281/A30905), the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019) and is part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00032/03) and the University of Bristol. LV acknowledges support from Czech Health Research Council by project NU21-03-00145. LJG is supported by a Cancer Research UK 25 (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). NT is supported by Cancer Research UK (PRCPJT-May22\100028) and is also part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council. EEV is supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant program (IIG_FULL_2024_029).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Some GWAS data were accessed through the OpenGWAS database API. Source (PMID) of all other GWAS data are listed in table 1.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Small amendments - Figures 6 and 7 now mentioned in-text, and typo conflating figure legends 1 and 7 amended.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
